Adicet Bio (FRA:1IJ) Volatility: 52.86% (As of Jun. 28, 2026)


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €6.60
! 3 Warning Signs
View Full Analysis

What is Adicet Bio Volatility?

Adicet Bio FRA:1IJ -5.04% 31 Volatility is 52.86% as of Jun. 28, 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-28), Adicet Bio's Volatility is 52.86%.

Adicet Bio  (FRA:1IJ) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Adicet Bio Volatility Related Terms

FRA:1IJ vs CUE, TELO, AARD: Volatility Comparison

For the Biotechnology subindustry, Adicet Bio's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Volatility distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Volatility falls into.


FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio  (FRA:1IJ) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 52.86% mean?
Adicet Bio (FRA:1IJ) has a Volatility of 52.86% as of Jun. 28, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's Volatility too high?
Adicet Bio's current Volatility is 52.86%. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Volatility compare to CUE and TELO?
Adicet Bio's Volatility of 52.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Adicet Bio and its competitors. Adicet Bio's current Volatility is 52.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Volatility of 52.86%. The current Volatility is 52.86%. Adicet Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Volatility is 52.86% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price